Loading clinical trials...
Loading clinical trials...
CoHort of Patients to Identify Biological and Imaging markerS of CardiovascUlar Outcomes in ST Elevation Myocardial Infarction
Ischemic heart disease is the leading cause of mortality with 7.2 million of death in industrialized countries (WHO data). Myocardial infarction corresponding to acute occlusion of a coronary artery is the most brutal form and the more severe ischemic myocardial disease. Every year in France, about 60,000 Myocardial infarctions hospitalized, 30,000 are diagnosed remotely and 30,000 are revealed by an inaugural sudden death. Although mortality from myocardial decreased by 30% over the past decade, the prognosis is pejorative and difficult to assess precisely. The management of the patient depends on these factors, and justifies an active search on these topics, including the mechanisms of the deleterious ventricular remodeling, myocardial inflammation, reperfusion injury which determines in particular the evolution to heart failure. Cohorts of patients with myocardial infarction are rare but can be very valuable by their clinical, laboratory and imaging well documented. They are the source of new hypotheses for research or interventions as well as the quality of care assessment tool. The main objective of this project is to identify new markers: biological and imaging, treatment response and prognosis after acute myocardial infarction. Secondary objectives of the HIBISCUS-STEMI cohort to establish a clinical database, completed by biological samples and by imaging data that can be used in the following areas: * Descriptive epidemiology of myocardial infarction and myocardial reperfusion * Pharmacoepidemiology and treatments observatory: safety, efficacy, indication of treatment in real life, costs * Assessment of the long-term effect of the treatment on the occurrence of heart failure and sudden death * Quality of life and personal consequences, family, professional and social myocardial infarction * Research of new diagnostic and prognostic biomarkers * Research projects (e.g. risk of developing kidney failure or stroke in patients with myocardial infarction compared to the general population).
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Hôpital Cardiovasculaire Louis Pradel
Bron, France
CHU Strasbourg
Strasbourg, France
CHU de Tours
Tours, France
Start Date
March 7, 2017
Primary Completion Date
June 5, 2023
Completion Date
June 5, 2023
Last Updated
September 10, 2025
281
ACTUAL participants
Blood sampling
BIOLOGICAL
ECG
PROCEDURE
MRI
DEVICE
Quality of life questionnaire
OTHER
Lead Sponsor
Hospices Civils de Lyon
NCT06438315
NCT07160491
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06678074